Pharmaceutical ProductCached Profile
ELLIPSYS
Active Ingredients (Generic):Unmapped
Therapeutic Area: Catheters
LIFETIME PROMOTIONAL SPEND
$7,164,061
General Payments Aggregated (2021–2024)
Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.
FDA Patient Safety Profile
Dynamic safety indicators compiled from official FDA product labels.
Active Clinical Trials
Clinical studies listing this drug as an active intervention.
Ellipsys Vascular Access System Post Market Surveillance (PS) Study PS200001 Reference DEN170004
COMPLETEDPhase NANCT04484220
Randomized Controlled Trial Comparing endoAVF Versus surgAVF
RECRUITINGPhase NANCT05654103
Vessel-Select Catheter System Feasibility Clinical Trial
COMPLETEDPhase NANCT02816398
Ellipsys Percutaneous Arteriovenous Fistula for Hemodialysis Access
UNKNOWNPhase N/ANCT03828253
Ellipsys Vascular Access Catheter System Clinical Trial
COMPLETEDPhase NANCT02363972
Top Funded Physicians (Cumulative)
Doctors receiving the highest aggregate promotional support for this product.
Dr. JEFFREY HULLMedical Doctor$955,559
Dr. STEPHEN PARKERMedical Doctor$941,831
Dr. DALE YOUNGMedical Doctor$797,741
Dr. DAVID SMIDMedical Doctor$600,997
Dr. MARK DE BLOISMedical Doctor$341,491
Drug Marketing Payments Log
Federal registry records of promotional speaking, consulting, meals, and offsets.
Year:
2024
2024
2023
2022
2021
Querying Open Payments Database
Fetching live CMS.gov records for ELLIPSYS...